ID   MOTN-1
AC   CVCL_2127
SY   MOTN1
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473538
DR   BioSample; SAMN10988469
DR   cancercelllines; CVCL_2127
DR   Cell_Model_Passport; SIDM01884
DR   DepMap; ACH-001130
DR   DSMZ; ACC-559
DR   DSMZCellDive; ACC-559
DR   GEO; GSM887340
DR   GEO; GSM888416
DR   IARC_TP53; 28296
DR   JCRB; JCRB1847
DR   PharmacoDB; MOTN1_963_2019
DR   Progenetix; CVCL_2127
DR   Wikidata; Q54906412
RX   PubMed=12127564;
RX   PubMed=14712486;
RX   PubMed=16827800;
RX   PubMed=22460905;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Characteristics: IL2 dependent.
CC   Doubling time: 24 hours (PubMed=12127564); ~30-40 hours (DSMZ=ACC-559).
CC   HLA typing: A*02:01:01,02:06:01; B*54:01:01,56:01:01; C*01:02:01,01:02:01; DPA1*02:02:02,02:02:02; DPB1*05:01:01,05:01:01; DQA1*03:01:01,03:03:01; DQB1*03:02:01,04:01:01; DRA*01:01:01,01:02:02; DRB1*04:05:01,08:02:01 (DSMZCellDive=ACC-559).
CC   Sequence variation: Gene fusion; HGNC; 29529; TBL1XR1 + HGNC; 15979; TP63; Name(s)=TBL1XR1-TP63 (PubMed=31160637).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.782+1G>A; ClinVar=VCV000634684; Zygosity=Homozygous; Note=Splice donor mutation (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.84%; Native American=0.4%; East Asian, North=73.72%; East Asian, South=24.39%; South Asian=0%; European, North=0%; European, South=0.64% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): DSMZ; JCRB
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 11,12 (JCRB)
ST   D13S317: 12 (DSMZ)
ST   D16S539: 9,11
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 30,31
ST   D2S1338: 19
ST   D3S1358: 16,17
ST   D5S818: 10
ST   D7S820: 10,12
ST   D8S1179: 15
ST   FGA: 21,24
ST   Penta D: 9
ST   Penta E: 16,18
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 14,19
DI   NCIt; C4664; T-cell large granular lymphocyte leukemia
DI   ORDO; Orphanet_86872; T-cell large granular lymphocyte leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_L208 ! PLT-2
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=12127564; DOI=10.1016/S0145-2126(02)00023-1;
RA   Matsuo Y., Drexler H.G., Takeuchi M., Tanaka M., Orita K.;
RT   "Establishment of the T-cell large granular lymphocyte leukemia cell
RT   line MOTN-1 carrying natural killer-cell antigens.";
RL   Leuk. Res. 26:873-879(2002).
//
RX   PubMed=14712486; DOI=10.1002/ijc.11647;
RA   Daibata M., Matsuo Y., Machida H., Taguchi T., Ohtsuki Y., Taguchi H.;
RT   "Differential gene-expression profiling in the leukemia cell lines
RT   derived from indolent and aggressive phases of CD56+ T-cell large
RT   granular lymphocyte leukemia.";
RL   Int. J. Cancer 108:845-851(2004).
//
RX   PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x;
RA   Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.;
RT   "Alterations in ATR in nasal NK/T-cell lymphoma and chronic active
RT   Epstein-Barr virus infection.";
RL   Cancer Sci. 97:605-610(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//